Immunohistochemical Expression of TGF-B1, SMAD4, SMAD7, TGFβRII and CD68-Positive TAM Densities in Papillary Thyroid Cancer

Koni Ivanova¹, Irena Manolova², Maria-Magdalena Ignatova¹, Maya Gulubova¹

¹Trakia University, Medical Faculty, Department of General and Clinical Pathology, Stara Zagora, Bulgaria; ²Trakia University, Medical Faculty, Department Molecular Biology, Immunology and Medical Genetics, Stara Zagora, Bulgaria

Abstract

BACKGROUND: Papillary thyroid carcinoma (PTC) accounts for 80% of the thyroid malignancies that are characterised by slow growth and an excellent prognosis. Over-expression of SMAD4 protein restores TGF-β signalling, determines a strong increase in anti-proliferative effect and reduces invasive potential of tumour cells expressing it.

AIM: The study aimed to analyse the immunohistochemical expression of TGF-β1 and its downstream phosphorylated SMAD4, element and of the inhibitory SMAD7 PTC variants and their association with the localisation of TAMs within the tumour microenvironment.

METHODS: For this retrospective study we investigated 69 patients immunohistochemistry with antibodies against TGF-β, TGF – β-RRI, SMAD4, SMAD7, CD68+ macrophages.

RESULTS: Patients with low infiltration with CD68+ cells in tumour stroma have significantly shorter survival (median of 129.267 month) compared to those with high CD68+ cells infiltration (p = 0.034). From the analysis of CD68+ cells in tumour border and tumour stroma correlated with expression of TGF-β1 / SMAD proteins, we observed that the positive expression of TGF-β1 in tumour cytoplasm, significantly correlated with increased number of CD68+ cells in tumour border (X2 = 5.945; p = 0.015).

CONCLUSION: TGF-β enhances motility and stimulates recruitment of monocytes, macrophages and other immune cells while directly inhibiting their anti-tumour effector functions.

Introduction

The transforming growth factor beta (TGF-β) impact on the immune system and tumour progression has been studied in general and in the development of thyroid cancer [1] [2] [3] [4] [5]. TGF-β activation is induced by several mechanisms including the expression of αvβ6 integrin, chymase, elastase, MMP9 etc. [6] [7] [8]. Activated TGF-β, after binding the TGF-β receptor II (TGF-RII) efficiently trans - activates TGF-β receptor I (TGF-RI) and directly promotes tyrosine phosphorylation [9]. Then TGF-β signalling activates R-Smads (SMAD2 and SMAD3 localised in the cytoplasm), through phosphorylation and after that allows the assembly of complexes with SMAD4. These complexes re-localise to the nucleus where they can regulate gene transcription [10]. This is the active TGF–β/SMAD–dependent pathway [2]. On the opposite, SMAD7 antagonises TGF–β/Smad – dependent signalling, and induces TGF-β receptor degradation and thus preventing SMAD2 and SMAD3 phosphorylation. SMAD7 leads a loss of TGF–β/SMAD-dependent pathway growth inhibition [10].

Normally and in the early phase of cancer TGF–β/SMAD-dependent pathway signalling inhibits
epithelial or cancer cell proliferation, and sometimes migration and invasiveness. These processes are studied in some cases with papillary thyroid cancer (PTC) [2][11].

In late phases tumour cells overcome TGF-β-induced suppressor effects on cell proliferation, an on the other hand tumour cells themselves may respond to this cytokine including other effects that contribute to tumour progression such as epithelial-mesenchymal transition (EMT), invasion and metastases [1][3]. TGF-β modulates the immune response that shields a tumour from immune surveillance [12][13].

PTC accounts for 80% of the thyroid malignancies that are characterised by slow growth and an excellent prognosis. However, 10–15% of cases exhibit aggressive behaviour with hallmarks of local invasion, distant metastases, treatment resistance, and motility [14][15].

TGF-β1 normally expressed and secreted by normal thyrocytes is a potent inhibitor of thyroid cell growth [16][17]. In tumours, TGF-β expression has been detected in 52-100% of PTC cases [18]. SMAD4 is found to be expressed in 75% of PTC cases [11][19] and every PTC cell line [19]. The SMAD7 expression has been detected in 80% of PTCs and PTC cell lines [11][20]. It has been found that TGFβRII mRNA transcripts are mainly expressed in 55% of PTCs compared to other thyroid cancers [21]. However, TGFβRII protein and mRNA expression display reduced levels in thyroid cancer cells [17][21].

TGF-β is abundant in the tumour microenvironment. It stimulates all cell populations including tumour cells, fibroblasts, and endothelial cells. Moreover, it enhances motility and recruitment of immune cells including monocytes, macrophages, NK cells, dendritic cells and T-cells while directly inhibiting their anti-tumour functions [22][23].

We decided to analyse the immunohistochemical expression of TGF-β1 and its downstream phosphorylated SMAD4, element and of the inhibitory SMAD7 in PTC variants and their association with the localisation of TAMs within the tumour microenvironment.

Material and Methods

Tumor samples

A series of 69 PTC cases has been retrieved from the Archives of the University Hospital in Stara Zagora, Bulgaria. The group of patients with PTC include cases with lymph node metastases (n = 2 or 2.9%) and without metastases and without metastases (n = 67 or 97.1%). The mean follow-up of 152.58 months; range from 1.64 to 197.07 has been done. PTC tumours were classified by size into tumours 1 cm or less in greatest dimension and tumours more than 1 cm in greatest dimension. There are 9 (13.0%) men and 60 (87.0%) women with age ranging from 22 to 81 years (mean 51.84 ± 13.756). Among the 69 PTC studied, 6 are ≤ 1 cm in diameter, and 63 tumours are larger. According to AJCC classification [24], 42 of the patients (60.8%) are in stage I, 20 of the patients (29.0%) are in stage II, 7 of the patients (10.2%) are in stage III, and no patients are in stage IV of the disease, (Table 1).

Table 1: Demographic, clinical data, histological and pathological characteristics of the tumours specimens according to the papillary thyroid tumour type

| Characteristics          | PTC N (%) |
|--------------------------|-----------|
| Age (mean ± SD)          | 54.17 ± 14.48 |
| Gender                   |           |
| Males                    | 9 (13.0)  |
| Females                  | 60 (87.0) |
| Pt classification        |           |
| T1-T2                    | 64 (92.7) |
| T3-T4                    | 5 (7.3)   |
| Lymph node metastases    |           |
| N0                       | 67 (97.1) |
| N1                       | 2 (2.9)   |
| Distant metastases       |           |
| M0                       | 69 (100)  |
| M1                       | 0 (0)     |
| Prim staging             |           |
| I stage                  | 42 (60.8) |
| II stage                 | 20 (28.9) |
| III stage                | 7 (10.2)  |
| IV stage                 | 0 (0)     |
| Differentiation          |           |
| Well                     | 69 (100)  |
| Poorly                   | 0 (0)     |
| Capsule                  |           |
| Non                      | 9 (13.0)  |
| Presence                 | 60 (87.0) |

**ANOVA test; ***; χ² test.

The study protocol has been approved by the Research Ethics Committee of University Hospital Stara Zagora.

All samples have been fixed in formalin and embedded in paraffin. Clinical data has been collected from the pathology reports, clinical files and Oncology Dispensary. H&E slides are retrieved from the archives, and they have been reviewed independently by two pathologists (MG and KI), and the tumours are classified using the WHO criteria [25]. Cases with doubtful PTC features are excluded.

Immunohistochemistry

Immunohistochemical staining is performed using the streptavidin-biotin technique as previously described [26]. Briefly, the endogenous peroxidase is blocked with 3% hydrogen peroxide in methanol for 10 min. Slides are incubated over night at room temperature with primary antibodies as follows: TGF-β (Clone sc-146) antibody in a dilution 1:50; monoclonal mouse anti-SMAD4 antibody (Clone sc - 7966) in a dilution 1:100; monoclonal mouse anti-SMAD7 antibody (Clone sc-11392) in a dilution 1:100; monoclonal mouse anti-TGFβ RII antibody (Clone sc-400) in a dilution 1:100-all produced from Santa Cruz Biotechnology, CA and monoclonal mouse anti-CD68
antibody (Clone KP11 M0814) ready-to-use, has been purchased from DAKO, Glostrup, Denmark. Then the slides are incubated with biotinylated secondary antibody and streptavidin-peroxidase complex for 2 hours and room temperature. Tissue sections with adequate positive and negative controls are used in every set of straining. Finally, sections are weakly counterstained with Mayer’s hematoxylin.

**Semi-quantitative assessment of TGF-β1, SMAD4, SMAD7, and TGFβRII**

The TGF-β1 expression is evaluated in the cytoplasm of tumour cells, TGFβRII expression is evaluated in tumour cell cytoplasm and membrane. SMAD4 and SMAD7 are evaluated in tumour cell cytoplasm and tumour cell nucleus. The immunohistochemical expression is evaluated as absent (0) and present (+) in tumour cell cytoplasm and nuclei. The TGF-β1 expression is also evaluated in the centre and periphery of all thyroid cancers (PTC) and in the respective remaining thyroid tissue, which has been used as an internal control. TGF-β1 expression, detected in thyrocytes in the control tissue is considered as the basal expression.

The expression of SMAD4 and SMAD7 is evaluated in all PTCS and in the respective remaining thyroid tissue, which has been used as an internal control tissue and considered as a basal expression. The expression of SMAD4 and SMAD7 has been not evaluated in the centre and periphery since it is considered too difficult to distinguish and therefore assumed as similar. Their expression is also graduated in two categories: absent and present (weak, moderate and intense staining) regarding each subcellular location (nuclear and cytoplasmic) separately.

**Macrophage counting**

A single pathologist (MG), who is blinded to the clinical assessments of each case, has scored the cases by counting, the number of CD68 TAMs in five independent fields of vision in a tumour and the invasive front under a 400 x magnification. CD68+ cell counts are expressed as the mean ± standard deviation.

**Patients’ slides with PTC assessed parameters**

**Clinicopathological parameters.** On H&E slides the following parameters are evaluated: capsule formation, capsule infiltration, vascular invasion and from protocols – extra-thyroid extension, metastases, multicentricity and tumour size of micro-carcinomas are checked. Patients are followed up until January 2016.

**Statistical analysis**

The SPSS 16.0 program for Windows was used for statistical analysis. The chi-squared test and Fisher’s exact test were used to compare the immunohistochemical staining and the clinicopathological parameters. ANOVA, Student – t-test, Mann-Whitney U test and Kruskal-Wallis test were applied for comparing the continuous variables depending on the normality of the distribution. Correlations were tested by Spearman and Person tests. Survival plots were drawn by the Kaplan–Meier test and survival periods were compared by log-rank test. The accepted level of significance was set at p < 0.05.

**Results**

**Components of TGF-β1 pathway in tumour tissue**

The TGF-β1 expression is detected mainly in tumour cell cytoplasm and is weakly demonstrated in tumour cell membranes. As compared to TGF-β1 expression, TGFβRII immune reaction is weaker in tumour cell cytoplasm (17.8%).

![Figure 1: Positive expression of TGF-β1 in tumour border (x 100)](image)

The TGF-β1 expression is not significantly correlated to any other clinical or pathological parameters. The cytoplasmic expression of TGF–β1 is directly proportional to the expression of both SMAD4 and SMAD7.

![Figure 2: Positive expression of TGF-β1 in tumour cytoplasm and tumour border in micro-papillary thyroid cancer (x 100)](image)

Lack of expression of TGF-β1 and SMAD7 in tumour cell cytoplasm is associated with capsule formations around tumour tissue. The SMAD4 nuclear expression is observed in 8.1% (n=4 patients) of tumours. There is not a significant difference between
TGF-β1 expression at the periphery of each a tumour and in its centre.

The expression of SMAD4 and SMAD7 in tumour nuclei is insignificant. The SMAD4 strong cytoplasmic expression is observed in 11 patients (24.4%) and weak positivity in 26 patients (57.8%).

Correlations between clinic-pathologic parameters, TGF-β1, TGFβRII, SMAD4 and SMAD7 and CD68-positive TAM densities

As histologic grade (type) of thyroid cancer is an important determinant of tumour behaviour and clinical prognosis, it is important to explore the effect of TAMs and TGF-β1 signalling pathway proteins on some clinic-pathologic parameters. There is no statistical correlation between the presence of TAMs (high or low density) and extra-thyroidal extension, capsular invasion and vascular invasion. The intense TGF-β1, SMAD4 and SMAD7 expression in tumour cell cytoplasm correlated with increased CD68+ TAMs number in tumour stroma (and for TGF-β1 in the invasive margin). There were no differences between patients with or without increased CD68+ positive TAMs in gender, age, tumour stage and grade (Table 3).

Table 2: Associations between the presence of CD68-positive cells in tumour border and the invasion front of tumours with the expression of molecules involved TGF-β1 signalling pathway

| Expression level of TGF-β1 signalling pathway molecules | Low numbers N (%) | High numbers N (%) | Low numbers N (%) | High numbers N (%) |
|--------------------------------------------------------|-------------------|-------------------|-------------------|-------------------|
| TGF-β1 in tumour stroma                                 |                   |                   |                   |                   |
| Negative n (%)                                          |                   |                   |                   |                   |
| Positive n (%)                                          |                   |                   |                   |                   |
| P value                                                 |                   |                   |                   |                   |
| TGF-β1 in tumour border                                 |                   |                   |                   |                   |
| Negative n (%)                                          |                   |                   |                   |                   |
| Positive n (%)                                          |                   |                   |                   |                   |
| P value                                                 |                   |                   |                   |                   |
| SMAD4 in tumour stroma                                  |                   |                   |                   |                   |
| Negative n (%)                                          |                   |                   |                   |                   |
| Positive n (%)                                          |                   |                   |                   |                   |
| P value                                                 |                   |                   |                   |                   |

Characterization of TAMs in PTC

The CD68 immunohistochemistry effectively stains macrophage cytoplasm. The TAM nuclei in PTC tissue are approximately 1/3 to ⅔ of the size of the nuclei of tumour cells. TAMs had cellular projections that wrap around tumour cells. TAMs and cancer cells appeared to be in close contact (Figure 6). TAMs formed distinctive canopy-like structures over some tumour cells.
From the analysis of CD68-positive cells in tumour border and tumour stroma correlated with expression of TGF-β1/SMAD proteins, we observed that the positive expression of TGF-β1 in tumour cytoplasm, significantly correlated with increased number of CD68-positive cells in tumour border ($\chi^2 = 5.945; \ p = 0.015$). Our work also revealed marginal significantly of Smad4 in tumor cytoplasm as compared to increased number of macrophages in tumor border ($\chi^2 = 3.606; \ p = 0.058$), and a tendency for Smad7 in tumor border correlated with increased number of CD68-positive cells in tumor stroma ($p = 0.115$), (Table 2 and 3).

**Table 3: Association between various clinic-pathological factors with the number of CD68-positive cells in tumour stroma and tumour border**

| Characteristics         | N   | CD68+ cell in tumour stroma mean ± SD | P value* | CD68+ cell in tumour border mean ± SD | P value* |
|-------------------------|-----|---------------------------------------|----------|---------------------------------------|----------|
| Age (mean ± SD)         |     |                                        |          |                                       |          |
| <53.28                  | 30  | 22.85 ± 20.27                         | 0.227    | 51.99 ± 9.49                          | 0.484    |
| >53.28                  | 39  | 16.46 ± 21.30                         |          | 34.51 ± 6.76                          |          |
| Gender                  |     |                                        |          |                                       |          |
| Males                   | 9   | 20.77 ± 23.08                         | 0.898    | 15.26 ± 18.48                         | 0.467    |
| Females                 | 60  | 19.71 ± 20.62                         |          | 28.17 ± 48.17                         |          |
| PI classification       |     |                                        |          |                                       |          |
| T1-T2                   | 64  | 20.82 ± 21.53                         | 0.177    | 31.97 ± 46.31                         | 0.565    |
| T3-T4                   | 5   | 35.23 ± 24.76                         |          | 36.44 ± 71.83                         |          |
| Lymph node metastases   |     |                                        |          |                                       |          |
| No                      | 2   | 30.55 ± 35.14                         |          | 30.55 ± 35.14                         |          |
| Yes                     | 67  | 22.07 ± 21.87                         | 0.385    | 22.07 ± 21.47                         | 0.647    |
| Ptnm staging            |     |                                        |          |                                       |          |
| I-II                    | 62  | 20.29 ± 21.20                         | 0.043    | 32.03 ± 47.56                         | 1.000    |
| III-IV                  | 7   | 33.89 ± 24.90                         |          | 34.80 ± 58.76                         |          |
| Differentiation         |     |                                        |          |                                       |          |
| Well                    | 69  | 26.16 ± 24.84                         |          | 41.44 ± 54.90                         | 0.452    |
| Poorly                  |     |                                        |          |                                       |          |
| Capsule                 | 9   | 19.50 ± 22.32                         | 0.177    | 29.98 ± 54.91                         | 0.937    |
| Present                 | 60  | 24.33 ± 22.38                         |          | 34.58 ± 49.11                         |          |

* Mann-Whitney U test.

Patients with low infiltration with CD68-positive cells in tumour stroma have significantly shorter overall survival (median of 129.267 months) compared to those with high CD68-positive cells infiltration (median is not reached, $p = 0.034$, Log-rank test).

**Discussion**

Our study demonstrates that TGF-β1, SMAD4, SMAD7 and TGFβRII protein expression is observed in PTC tumour cells and these proteins are overexpressed in tumour cells as compared to the surrounding normal thyroid tissue. We couldn’t find any difference in the expression of TGF-β1 signalling proteins in tumour centre and periphery as did Eloy et al. (2012). Moreover, the number of patients with PTC is similar in both studies (75 patients in Eloy at al., 2012; 80 patients in our study). Our PTCs are mainly well-circumscribed, and we don’t subdivide them to well-circumscribed papillary thyroid cancer (WCPTC) and poorly-circumscribed papillary thyroid cancer (PCPTC), respectively as Eloy et al., 2012 do. These authors establish that in WCPTCs the differences of TGF-β1 expression from centre to the periphery are very insignificant. We detect that TGF-β1, SMAD4 and SMAD7expression in all cases of PTC and control tissues (except in 17 TGF-β1 negative cases) are similar to that reported previously [2] [11] [18]. SMAD4 cytoplasmic/nuclear expression is considered to be indicative of a functioning TGF-β (SMAD-dependent pathway) [11] [19]. In our study, it is demonstrated that all tumours expressed SMAD4 in their cytoplasm to a lesser extent than TGF-β1. It is known that the lower expression of SMAD4 was mainly responsible for the impairment TGF-β signalling [19]. In a previous study, the authors demonstrated that SMAD4 mutations are frequent in PTC [27] when sequencing of the entire coding part of the SMAD4 gene was performed. In later study D’Inzeo et al., 2010 hypothesised that the cause of lower expression of SMAD4 could be found in alteration of major components of translational machinery, which are frequently altered in human neoplasms [28]. The molecular mechanism that controls subcellular localisation and activation of Smad proteins is crucial for TGF-β signalling, and it is not yet fully clarified. It has been shown that SMAD4 nuclear expression is reduced in cancer [19]. However, SMAD4 undergoes continuous nucleocytoplasmic shuttling on its own, independently of TGF-β signalling [29]. The levels and the duration of residence in the nucleus of SMAD4 are important events for the response of TGF-β in the cells, and the intensity and duration of the TGF-β-Smad response is important for the signalling specificity. There we demonstrate the reduction of SMAD4 protein expression in PTC tumour cell cytoplasm and in nuclei which may be indicative of a loss of TGF-β cytoplasmic response (loss of tumour cell growth inhibition). Therefore the reduction of SMAD4 cytoplasmic and loss of nuclear protein expression is associated with the embarrassment of the TGF-β signalling pathway.SMAD7 nuclear expression was associated to loss of TGF-β/Smad-dependent pathway inhibition [2], and its expression is found to be at basal levels and lesser as compared to TGF-β1 and SMAD4 expression of the cases in the presents series-similarly to other reports [11]. TGF-βRII mRNA overexpression was detected in PTC cell lines [17]. In our study, TGF-βRII expression was lower as compared to TGF-β1 expression in tumour cells of PTC.

We demonstrate that all investigated from TGF-β/Smad pathway proteins in our study are associated with increased CD68 TAMs density in tumour stroma and the border of PTCs. It has been shown that large cohorts of cancers including thyroid cancer with high-density TAMs have poor prognoses and poor survival rates [30].

The impact of TGF-β signalling in the immune system was well documented. TGF-β promotes recruitment of monocytes, and it has been hypothesised that TGF-β can promote monocytes to

Open Access Maced J Med Sci. 2018 Mar 15; 6(3):435-441.
macrophage differentiation [1]. Moreover, TGF-β stimulation of macrophages had been shown to attenuate macrophages associated suppression of CD4+ T cell proliferation. TGF-β signalling is needed for the alternative activation of macrophages to M2 status. It has been shown that lack of TGF-βRII leads to the defects in the expression of a set of genes that form the hallmark of the M2 polarising program [22].

Therefore, TGF-β enhances motility and stimulates recruitment of monocytes, macrophages and other immune cells while directly inhibiting their anti-tumour effector functions [31]. As a result, TGF-β associated inflammation can promote tumorigenesis due to secretion of growth-factors, cytokines, chemokines, etc. from the recruited immune cells that stimulated cancer cell growth, motility and invasion.

References

1. Bierie B, Moses HL. Transforming growth factor beta (TGF-β) and inflammation in cancer cytokine. Growth Factor Rev. 2010; 21(1):4959.

2. Eloy C, Santos J, Cameselle-Teijeiro C, Soares P, Simoes-Sobrinho M. TGF-beta/Smad pathway and BRAF mutation play different roles in circumscribed and infiltrative papillary thyroid carcinoma. Virchows Arch. 2012; 460:587-600.

3. Cunha LL, Marcello MA, Ward LS. The role of cytokines, chemokines, etc. from the recruited immune cells that associated inflammation can promote tumorigenesis for the alternative activation of macrophages to M2 status. It has been shown that lack of TGF-βRII leads to the defects in the expression of a set of genes that form the hallmark of the M2 polarising program [22].

4. Miyazono K, Ehata S, Koinuma D. Tumor necrosis factor (TNF-α) and transforming growth factor beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell. 1999; 96(3):319-328.

5. Zhang YE. Non-Smad pathway in TGF-β signaling. Cell Res. 2009; 19(1):128-139. [https://dx.doi.org/10.1038/cr.2008.328]

6. Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J, Pittet JP, Kaminska N, Garalt C, Matthay MA, Rifkin DB, Sheppard D. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell. 1999; 96(3):319-328.

7. Taipale J, Loh J, Saarinen J, et al. Human mast cell chymase and leukocyte elastase release latent transforming growth factor-beta 1 from the extracellular matrix of cultured human epithelial and endothelial cells. J Biol Chem. 1995; 270:4689-4696. [https://dx.doi.org/10.1074/jbc.270.9.4689]

8. Yu Q, Slamovick I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis. Genes Dev. 2000; 14(2):163-176. [PMID:10652271] PMCID:PMC316345

9. Lee MK, Pardoux C, Hall MC, Lee PS, Warburton D, Qing J, Smith SM, Derynck R. TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA. Embo J. 2007; 26(17):3957-3967. [https://dx.doi.org/10.1038/sj.emboj.7601818] PMID:17673906 PMCID:PMC1994119

10. Elliot RL, Bloge GC. Role of transforming growth factor beta in human cancer. J Clin Oncol. 2005; 23:2078-2093. [https://dx.doi.org/10.1200/JCO.2005.02.047] PMID:15774796

11. Matsuo SE, Fiore AP, Siqueiruatu SM, Ebina KN, Frugulietti CU, Ferro MC, Kulcsar MA, Kimura ET. Expression of SMAD proteins, TGF-beta/active in signaling mediators, in human thyroid tissues. Arq Bras Endocrinol Metab. 2010; 54: 405-412. [https://dx.doi.org/10.1590/S0004-27302010000100010]

12. Vendramini-Costa DB and Carvalho JE. Molecular link mechanisms between inflammation and cancer. Current Pharmaceutical Design. 2012; 18:3831-3852. [https://dx.doi.org/10.2174/1381612128020083707] PMID:22632748

13. Fabregat I, Fernando J, Mainez J, Sancho P. TGF-β signaling in cancer treatment. Current Pharmaceutical Design. 2013; 29(4):755–63.

14. Hay ID, Thompson GB, Grant CS, Bergstralh EJ, Gorman CA, Maurer MS, McIver B, Mullan BP. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940–1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg. 2002; 26:879-885. [https://dx.doi.org/10.1007/s00268-002-6612-1] PMID:12016468

15. Wang NI, Jiang R, Yang J-Y, Tang C, Yang L, Xu M, Jiang Q-F, Lin Z-M. Expression of TGF-β1, SNAI1 and MMP-9 is associated with lymph node metastasis in papillary thyroid carcinoma. J Mol Histol, 2014; 45:391-399. [https://dx.doi.org/10.1007/s10735-013-9557-9] PMID:24276590

16. Colletta G, Cirafici AM, Di Carlo A. Dual effect of transforming growth factor beta on rat thyroid cells: inhibition of thyrotrpin-induced proliferation and reduction of thyroid-specific differentiation markers. Cancer Res. 1989; 49(13):3457-62.

17. Mincione G, Tarantelli C, Vianale G, Di Marcantonio MC, Cotellese R, Francomano F, Di Nicola M, Constantini E, Cichella A, Muraro R. Mutual regulation of TGF-β1, TBR1 and ErbB receptors expression in human thyroid carcinomas. Exp. Cell Res. 2014; 327:24-36. [https://dx.doi.org/10.1016/j.yexcr.2014.06.012] PMID:24973511

18. Kimura ET, Kopp P, Zbarren J, Asmis LM, Ruchti C, Maciel RM, Studer H. Expression of Transforming Growth Factor β1, β2, and β3 in Multinodular Goiters and Differentiated Thyroid Carcinomas: A Comparative Study. Thyroid. 1999; 9:119-125. [https://dx.doi.org/10.1089/thy.1999.9.119] PMID:10090310

19. D’Inzeo S, Nicollusi A, Ricci A, Mancini P, Porcellini A, Nardi F, Coppa A. Role of reduced expression of SMAD4 in papillary thyroid carcinoma. J Mol Endocrinol. 2010; 45:229-244. [https://dx.doi.org/10.1530/JME-09-0044] PMID:20685810

20. Cerutti JM, Ebina KN, Matsumoto K, Matsuo SE, Fiore AP, Siqueiruatu SM, Ebina KN, Frugulietti CU, Ferro MC, Kulcsar MA, Kimura ET. Expression of Smad4 and Smad7 in human thyroid follicular carcinoma cell lines. J Endocrinol Invest. 2003; 26:516-521. [https://dx.doi.org/10.1007/BF03345213] PMID:12952364

21. Lazzereschi D, Ranieri A, Mincione G, Taccogna S, Nardi F, Colletta G. Human malignant thyroid tumors displayed reduced levels of transforming growth factor beta receptor type II messenger RNA and protein. Cancer Res. 1997; 57(10):2071-2076. [PMID:915507]

22. Gong D, Shi W, Yi S-J, Chen H, Groffen J, Heisterkamp N. TGF-β signaling plays a critical role in promoting alternative macrophage activation. BMC Immunology. 2012; 13:31-41. [https://dx.doi.org/10.1186/1471-2172-13-31] PMID:22703233 PMCID:PMC3406950

23. Li MO, Yisong Y, Wan SS et al. Transforming-growth factor-beta regulation of immune responses. Annu Rev Immunol. 2006; 24:99-146. [https://dx.doi.org/10.1146/annurev.immunol.24.021605.090737] PMID:16551245

24. Lang BH, Lo CY, Chan WF, Lam KY, Wan KY. Staging systems for papillary thyroid carcinoma: a review and comparison. Ann Surg. 2007; 245:366-378. [https://dx.doi.org/10.1097/SLA.0b013e3182699f9b] PMID:17435454 PMCID:PMC1877011

25. DeLellis RA, Lilly RV, Heitz PU, et al. Pathology and genetics of tumors of endocrine organs World Held Organization Classifications of tumors. Lyon: IARC press, 2004.
26. Gulubova MV, Ananiev J, Yovchev Y, Julianov A, Karashmalakov A, Vlaykova T. The density of macrophages in colorectal cancer is inversely correlated to TGF-β expression and patients' survival. J Mol Histol. 2013; 44:679-692. https://doi.org/10.1007/s10735-013-9520-9 PMid:23801404

27. Lazzereschi D, Nardi F, Turco A, Ottini L, D'Amico C, Mariani-Constantini R, Gulino A, Coppa A. A complex pattern of mutations and abnormal splicing of Smad4 is present in thyroid tumors. Oncogene. 2005; 24:5344-5354. https://doi.org/10.1038/sj.onc.1208603 PMid:15940269

28. Rosenwald IB. The role of translation in neoplastic transformation from a pathologists point of view. Oncogene. 2004; 23:3230-3247. https://doi.org/10.1038/sj.onc.1207552 PMid:15094773

29. Hill CS. Nucleocytoplasmic shuttling of Smad proteins. Cell Research. 2009; 19:36-46. https://doi.org/10.1038/cr.2008.325 PMid:19114992

30. Jung KY, Cho SW, Kim YA, Kim D et al. Cancers with higher density of tumor-associated macrophages was associated with poor survival rates. J Pathol Translat Med. 2015; 49:318-324. https://doi.org/10.4132/jptm.2015.06.01 PMid:26081823 PMCid:PMC4508569

31. Li Mo et al. Transforming growth factor beta and the immune responses. Annu Rev Immunol. 2006; 24: 99-146. https://doi.org/10.1146/annurev.immunol.24.021605.090737 PMid:16551245